CU20120145A7 - Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis - Google Patents

Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis

Info

Publication number
CU20120145A7
CU20120145A7 CU2012000145A CU20120145A CU20120145A7 CU 20120145 A7 CU20120145 A7 CU 20120145A7 CU 2012000145 A CU2012000145 A CU 2012000145A CU 20120145 A CU20120145 A CU 20120145A CU 20120145 A7 CU20120145 A7 CU 20120145A7
Authority
CU
Cuba
Prior art keywords
endometriosis
treatment
ovarian
aromatase
gestagens
Prior art date
Application number
CU2012000145A
Other languages
English (en)
Inventor
Arto Pakkalin
Rudolf Knauthe
Heinz Schmitz
Christine Talling
Harri Jukarainen
Henriikka Korolainen
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44021822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20120145(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20120145A7 publication Critical patent/CU20120145A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

El contenido de la presente invención para el tratamiento de endometriosis consiste en proporcionar una forma farmacéutica parenteral (sistema de administración) para la liberación controlada de un inhibidor de aromatasa (AI) con una tasa de liberación diaria, que no induce una estimulación de los ovarios por reacoplamiento negativo del eje hipófisis ovario(que provocaría una secreción de gonadotropinas y estimulación del crecimiento folicular ovárico), y de un gestágeno con una tasa de liberación diaria inferior a la dosis inhibidora de la ovulación, que pone a disposición una acción anticonceptiva sobre la base de acciones locales (por ejemplo, reducción y espesamiento de la mucosa cervical, para impedir que suban los espermatozoides, efectos sobre el endometrio y sobre la motilidad de las trompas, a fin de evitar la implantación y el transporte de óvulos).
CU2012000145A 2010-03-31 2012-09-28 Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis CU20120145A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010003494A DE102010003494A1 (de) 2010-03-31 2010-03-31 Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
PCT/EP2011/054737 WO2011120925A1 (de) 2010-03-31 2011-03-28 Parenterale arzneiform, die aromatasehemmer und gestagene freisetzt, für die behandlung von endometriose

Publications (1)

Publication Number Publication Date
CU20120145A7 true CU20120145A7 (es) 2013-05-31

Family

ID=44021822

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000145A CU20120145A7 (es) 2010-03-31 2012-09-28 Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis

Country Status (41)

Country Link
US (2) US20130131027A1 (es)
EP (1) EP2552404B1 (es)
JP (2) JP6012048B2 (es)
KR (1) KR20130010047A (es)
CN (1) CN103002873B (es)
AR (1) AR080861A1 (es)
AU (1) AU2011234587B2 (es)
BR (1) BR112012024739A2 (es)
CA (1) CA2794790A1 (es)
CL (1) CL2012002722A1 (es)
CO (1) CO6630125A2 (es)
CR (1) CR20120493A (es)
CU (1) CU20120145A7 (es)
CY (1) CY1116187T1 (es)
DE (1) DE102010003494A1 (es)
DK (1) DK2552404T3 (es)
DO (1) DOP2012000255A (es)
EA (1) EA025582B1 (es)
EC (1) ECSP12012176A (es)
ES (1) ES2533101T3 (es)
GT (1) GT201200267A (es)
HR (1) HRP20150294T1 (es)
IL (1) IL222056A (es)
MA (1) MA34099B1 (es)
ME (1) ME02159B (es)
MX (1) MX2012011329A (es)
MY (1) MY160353A (es)
NZ (1) NZ602698A (es)
PE (1) PE20130524A1 (es)
PH (1) PH12012501944A1 (es)
PL (1) PL2552404T3 (es)
PT (1) PT2552404E (es)
RS (1) RS53876B1 (es)
SG (1) SG184111A1 (es)
SI (1) SI2552404T1 (es)
TN (1) TN2012000468A1 (es)
TW (2) TW201632184A (es)
UA (1) UA109655C2 (es)
UY (1) UY33303A (es)
WO (1) WO2011120925A1 (es)
ZA (1) ZA201206869B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
BR112017025097B1 (pt) * 2015-05-27 2021-05-11 Quest Diagnostics Investments Llc método para quantificação espectrométrica de massa de analitos extraídos de um dispositivo de microamostragem
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3393452B1 (en) * 2015-12-21 2021-08-04 Bayer Oy Method for manufacturing a drug delivery device
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
US20240122885A1 (en) * 2021-02-12 2024-04-18 The Regents Of The University Of California Endometriosis-Related Methods and Compositions
CA3251695A1 (en) * 2022-02-22 2023-08-31 Celanese Eva Performance Polymers Llc Intravaginal ring device for the administration of an aromatase inhibitor
CN115804762B (zh) * 2022-12-20 2024-05-31 浙江大学 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FI20000572A7 (fi) * 2000-03-13 2001-09-14 Schering Oy Implantaattien asettamiseen tarkoitettu laite
CA2434611A1 (en) * 2001-01-26 2002-09-19 Pharmacia Italia Spa Combined method for treating hormono-dependent disorders
GB0120147D0 (en) * 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017973A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
GB0320238D0 (en) * 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
US20050101579A1 (en) * 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
AR066166A1 (es) * 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US20110033519A1 (en) 2009-08-07 2011-02-10 Leong Madeline Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use

Also Published As

Publication number Publication date
AU2011234587A1 (en) 2012-10-25
CN103002873B (zh) 2015-02-18
CA2794790A1 (en) 2011-10-06
PL2552404T3 (pl) 2015-05-29
NZ602698A (en) 2014-08-29
TWI576107B (zh) 2017-04-01
PH12012501944A1 (en) 2017-01-06
SI2552404T1 (sl) 2015-04-30
TW201632184A (zh) 2016-09-16
TW201201799A (en) 2012-01-16
HRP20150294T1 (hr) 2015-06-19
IL222056A (en) 2016-03-31
GT201200267A (es) 2014-06-04
JP2016164200A (ja) 2016-09-08
DE102010003494A1 (de) 2011-10-06
CY1116187T1 (el) 2017-02-08
EA201201358A1 (ru) 2013-04-30
EA025582B1 (ru) 2017-01-30
KR20130010047A (ko) 2013-01-24
AR080861A1 (es) 2012-05-16
CN103002873A (zh) 2013-03-27
BR112012024739A2 (pt) 2016-06-07
MX2012011329A (es) 2012-11-30
PT2552404E (pt) 2015-03-30
HK1179531A1 (en) 2013-10-04
RS53876B1 (sr) 2015-08-31
EP2552404B1 (de) 2015-01-21
UA109655C2 (uk) 2015-09-25
MA34099B1 (fr) 2013-03-05
EP2552404A1 (de) 2013-02-06
MY160353A (en) 2017-02-28
AU2011234587B2 (en) 2015-07-09
SG184111A1 (en) 2012-10-30
TN2012000468A1 (en) 2014-01-30
ME02159B (me) 2015-10-20
WO2011120925A1 (de) 2011-10-06
JP6012048B2 (ja) 2016-10-25
ES2533101T3 (es) 2015-04-07
UY33303A (es) 2011-10-31
PE20130524A1 (es) 2013-04-26
CL2012002722A1 (es) 2013-01-18
CO6630125A2 (es) 2013-03-01
DK2552404T3 (en) 2015-03-30
US20150359802A1 (en) 2015-12-17
JP2013523683A (ja) 2013-06-17
ECSP12012176A (es) 2012-10-30
US20130131027A1 (en) 2013-05-23
ZA201206869B (en) 2016-01-27
DOP2012000255A (es) 2013-04-30
CR20120493A (es) 2012-11-22

Similar Documents

Publication Publication Date Title
UY33303A (es) Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis
PE20142239A1 (es) Sistemas intrauterinos, dispositivos de insercion diu, y metodos relacionados y kits de los mismos
AR117670A2 (es) Modulador del receptor de andrógeno y sus usos
BR112019006227A2 (pt) métodos de tratamento de leiomioma uterino e endometriose
MX344831B (es) Composiciones para el transplante floral fecal y metodos para elaborar y utilzar las mismas y dispositivos para suministrar las mismas.
BR112015003094A8 (pt) dispositivo contraceptivo intrauterino
CL2016003295A1 (es) Dosificación intermitente de un inhibidor de mdm2.
JO3732B1 (ar) مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض
CR10985A (es) Progesterona para la prevencion de nacimiento pretermino espontaneo
PH12014502516B1 (en) Formulations and methods for vaginal delivery of antiprogestins
RU2015103116A (ru) Новый штамм lactobacillus crispatus
MX384159B (es) Formulaciones y métodos para el suministro vaginal de antiprogestinas.
MX2017014844A (es) Regimen modulador selectivo de los receptores de progesterona (sprm).
AR095834A1 (es) Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica
TH133904A (th) รูปแบบยาที่ไม่ผ่านทางเดินซึ่งปลดปล่อยสารยับยั้งอะโรมาเทสและเจสตาเจนเพื่อรักษาภาวะเยื่อบุมดลูกเจริญผิดที่
DOP2007000122A (es) Forma farmacologica peroral para anticoncepcion
UA100790U (uk) Спосіб лікування симптомної лейоміоми матки
Endometriosis et al. ONEXAMINATION QUIZ
TH115297A (th) ระบบที่อยู่ภายในมดลูก (Intrauterine System) สำหรับการใช้ในการบำบัดทางการแพทย์
Nayot Headache: 3 case reports
Gastal et al. Reuse of vaginal devices after autoclaving on rates parameters in sheep.
MX2016008174A (es) Anticonceptivo espermicida.
UA99956U (uk) Спосіб комбінованого лікування лейоміоми матки у поєднанні з аденоміозом
UA99532U (uk) Спосіб підвищення запліднюваності кобил проведенням санації внутрішніх статевих органів